CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (AMEX:JAV) announced late yesterday at its New York analyst and investor day that the UK approval of Dyloject (its proprietary injectable formulation of diclofenac sodium) heralds its emergence as a commercial entity. Previously a specialty pharmaceutical company engaged in the development of pain products, it is now fully engaged in commercialization and revenue generation. Company senior management reviewed the key events leading to this point:
